John Valliant, Chief Executive Officer at Fusion Pharmaceuticals Inc. (FUSN), sold 2,181 shares at $7.58 ($16K) on 2022-04-06, disclosed to the SEC on 2022-04-08.
Scheduled sale ($16k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.58 | 100 | $758 | 4.6% |
| 2 | $7.56 | 1,255 | $9K | 57.7% |
| 3 | $7.52 | 826 | $6K | 37.7% |
| Total | $7.55 avg | 2,181 | $16K | 100% |
| Filing → |
| FUSN | SELL | 2022-04-13 | $432K | — | Filing → |
| FUSN | SELL | 2022-04-05 | $29K | — | Filing → |
| FUSN | SELL | 2022-04-01 | $2K | — | Filing → |